Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Lung Cancer
•
Thoracic Malignancies
•
Medical Oncology
For patients with resected NSCLC, is there a role for using commercial molecular profiling to determine benefit of giving adjuvant chemotherapy vs giving adjuvant therapy based on stage alone?
Related Questions
What are your top takeaways in Thoracic Cancers from ASCO 2023?
How do you define an adequate EBUS when staging NSCLC?
How would you manage a left sided triple negative breast cancer with a concurrent left sided locally advanced non-small cell lung cancer?
Is there a role for pemetrexed in the treatment of metastatic adenosquamous NSCLC?
What is your approach for an RA patient with lung cancer who is starting immunotherapy?
Would you add ALK-targeted therapy for patients with EGFR L858R-mutant lung adenocarcinoma who progress on targeted therapy and develop a concomitant STRN-ALK fusion?
How are you approaching patients with early-stage NSCLC who progress on neoadjuvant chemo-immunotherapy and are no longer surgical candidates?
Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?
Is dyspnea without radiation pneumonitis a side effect of lung radiation?
Would you ever consider repeating chemoradiation for patients with locally recurrent small cell lung cancer after prior chemoradiation for LS-SCLC?